Pharmaceutical company decisions on clinical trial continuity have largely remained stable since end of April Clinical trial continuity among Selected clinical trial continuity statements – top 50 pharma April/May 2020 (n=30 companies with public statements) “While Biogen does expect there will be some impact to timelines for some of its clinical programs, it still expects the vast majority of the 13% 10 remaining near-term readouts to occur before the end of 2021.” Delay existing enrollment “Clinical trials are continuing and we are leveraging our digital tools 10% to limit the disruption caused by the pandemic. We are seeing Delay new 53% slowdowns in new enrollments in ongoing clinical studies and start- trials only Attempt to up with new studies. At this time we remain confident the impact on maintain and our ongoing clinical trials is manageable. Looking ahead for the 23% leverage remainder of the year, we do not expect delays in our planned continuity 2020 regulatory submissions.” Delay new trials solutions on case and existing by case basis “While some of our clinical trial sites remain paused for new patient patient enrollment recruitment, we endeavor to continue our clinical research programs with the wellbeing of our patients as our guiding principle. We assess the situation continuously and where it is safe for patients and in line with local regulations, we have restarted patient recruitment at some sites for most of our ongoing studies..” Source: IQVIA secondary research; company websites and press releases. IQVIA Global Executive Briefing: COVID-19 June 2020; Copyright 2020 IQVIA. 15